We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
IDEX (IEX) Stock Up on Q2 Earnings Beat, 2022 EPS View Up
Read MoreHide Full Article
IDEX Corporation (IEX - Free Report) reported impressive second-quarter 2022 results. IEX’s earnings surpassed the Zacks Consensus Estimate by 6.3%, whereas sales beat the same by 3.8%. Following this stellar performance, shares of IEX gained 2.8% in after-hours trading on Jul 26.
In the reported quarter, IDEX’s adjusted earnings were $2.02 per share, beating the Zacks Consensus Estimate of $1.90. On a year-over-year basis, the bottom line increased 25.5% from the year-ago quarter’s $1.61. Healthy segmental results favorably impacted the quarter’s earnings.
Earnings for the second quarter exceeded management’s projection of $1.85-$1.90.
Revenue Details
In the quarter under review, IDEX’s net sales were $796 million, reflecting year-over-year growth of 16%. Organic sales in the quarter increased 12% year over year, higher than 8-9% growth expected by IEX. Acquired assets boosted sales 7%. Foreign-currency translation left a negative impact of 3%.
IDEX’s top line surpassed the Zacks Consensus Estimate of $767 million.
IEX reports net sales under three business segments, results of which are discussed below:
Revenues from Fluid & Metering Technologies totaled $299.9 million, increasing 19% year over year. Organic sales were up 13% and synergies from acquired assets added 9%. Foreign-currency translation left a negative impact of 3%.
Revenues from Health & Science Technologies totaled $326 million, reflecting year-over-year growth of 19%. Organic sales in the quarter increased 12% year over year, while acquisitions/divestitures boosted sales 10%. Foreign currency translation left a negative impact of 3%.
Revenues from Fire & Safety/Diversified Products totaled $171.2 million, rising 7% year over year. The results were aided by an 11% increase in organic sales but suffered 4% forex woes.
In the quarter under review, IDEX’s cost of sales increased 15.6% year over year to $439.2 million. The adjusted gross profit was $ 357.3 million, up 16.0% year over year, while the adjusted gross margin of 44.9% was in line with the figure reported in the year-ago quarter.
Selling, general and administrative expenses increased 15.8% year over year to $167.5 million. The same represented 21% of revenues. Adjusted earnings before interest, tax, depreciation and amortization (EBITDA) in the quarter under review increased 13.5% year over year to $219.2 million. The adjusted EBITDA margin decreased 60 bps year over year to 27.5%.
The adjusted operating income was $189.8 million, up 13.5% year over year, whereas the margin was 2.8%, down 60 bps. Interest expenses in the quarter dropped 15.2% year over year to $9.5 million.
Balance Sheet and Cash Flow
While exiting the second quarter, IDEX’s cash and cash equivalents decreased 34.8% to $557.8 million compared with $855.4 million recorded at the end of fourth-quarter 2021. Long-term debt was $1,190.9 million compared with $1,190.3 million recorded in the end of fourth-quarter 2021.
In the first six months of 2022, IDEX generated net cash of $278 million from operating activities, increasing 29.4% from the year-ago quarter’s level. Capital used for purchasing property, plant and equipment was $31.7 million compared with $30.6 million in first-six months of 2021. Free cash flow was $160.3 million, down 24.4% year over year.
IEX paid out dividends totaling $86.9 million and repurchased common stocks worth $110.4 million.
Amount spent on acquisitions, net of acquired cash, totaled $234.9 million. On May 2, 2022, IDEX completed the acquisition of KZValve.
Outlook
For third-quarter 2022, IDEX anticipates adjusted earnings of $1.98-$2.03 per share and 9-10% growth in organic sales from the respective year-ago period’s readings.
IEX predicts EPS of $1.80-$1.85 per share for third-quarter 2022.
For 2022, IDEX anticipates adjusted earnings of $7.88-$7.98 per share, higher than $7.50-$7.63 per share projected earlier. Full-year earnings are predicted to be $7.19-$7.29, higher than $6.87-$7.00 per share expected earlier.
Organic sales are predicted to grow approximately 10% for 2022.
Zacks Rank & Stocks to Consider
IEX currently carries a Zacks Rank #3 (Hold). Some better-ranked companies from the industrial products sector are discussed below:
GEF’s earnings estimates have increased 17.8% for fiscal 2022 (ending October 2022) in the past 60 days. Its shares have risen 16.7% in the past six months.
Titan International, Inc. presently flaunts a Zacks Rank of 1. Its earnings surprise in the last four quarters was 56.4%, on average.
In the past 60 days, TWI’s earnings estimates have increased 43.3% for 2022. The stock has surged 66.1% in the past six months.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
IDEX (IEX) Stock Up on Q2 Earnings Beat, 2022 EPS View Up
IDEX Corporation (IEX - Free Report) reported impressive second-quarter 2022 results. IEX’s earnings surpassed the Zacks Consensus Estimate by 6.3%, whereas sales beat the same by 3.8%. Following this stellar performance, shares of IEX gained 2.8% in after-hours trading on Jul 26.
In the reported quarter, IDEX’s adjusted earnings were $2.02 per share, beating the Zacks Consensus Estimate of $1.90. On a year-over-year basis, the bottom line increased 25.5% from the year-ago quarter’s $1.61. Healthy segmental results favorably impacted the quarter’s earnings.
Earnings for the second quarter exceeded management’s projection of $1.85-$1.90.
Revenue Details
In the quarter under review, IDEX’s net sales were $796 million, reflecting year-over-year growth of 16%. Organic sales in the quarter increased 12% year over year, higher than 8-9% growth expected by IEX. Acquired assets boosted sales 7%. Foreign-currency translation left a negative impact of 3%.
IDEX’s top line surpassed the Zacks Consensus Estimate of $767 million.
IEX reports net sales under three business segments, results of which are discussed below:
Revenues from Fluid & Metering Technologies totaled $299.9 million, increasing 19% year over year. Organic sales were up 13% and synergies from acquired assets added 9%. Foreign-currency translation left a negative impact of 3%.
Revenues from Health & Science Technologies totaled $326 million, reflecting year-over-year growth of 19%. Organic sales in the quarter increased 12% year over year, while acquisitions/divestitures boosted sales 10%. Foreign currency translation left a negative impact of 3%.
Revenues from Fire & Safety/Diversified Products totaled $171.2 million, rising 7% year over year. The results were aided by an 11% increase in organic sales but suffered 4% forex woes.
IDEX Corporation Price and Consensus
IDEX Corporation price-consensus-chart | IDEX Corporation Quote
Margin Profile
In the quarter under review, IDEX’s cost of sales increased 15.6% year over year to $439.2 million. The adjusted gross profit was $ 357.3 million, up 16.0% year over year, while the adjusted gross margin of 44.9% was in line with the figure reported in the year-ago quarter.
Selling, general and administrative expenses increased 15.8% year over year to $167.5 million. The same represented 21% of revenues. Adjusted earnings before interest, tax, depreciation and amortization (EBITDA) in the quarter under review increased 13.5% year over year to $219.2 million. The adjusted EBITDA margin decreased 60 bps year over year to 27.5%.
The adjusted operating income was $189.8 million, up 13.5% year over year, whereas the margin was 2.8%, down 60 bps. Interest expenses in the quarter dropped 15.2% year over year to $9.5 million.
Balance Sheet and Cash Flow
While exiting the second quarter, IDEX’s cash and cash equivalents decreased 34.8% to $557.8 million compared with $855.4 million recorded at the end of fourth-quarter 2021. Long-term debt was $1,190.9 million compared with $1,190.3 million recorded in the end of fourth-quarter 2021.
In the first six months of 2022, IDEX generated net cash of $278 million from operating activities, increasing 29.4% from the year-ago quarter’s level. Capital used for purchasing property, plant and equipment was $31.7 million compared with $30.6 million in first-six months of 2021. Free cash flow was $160.3 million, down 24.4% year over year.
IEX paid out dividends totaling $86.9 million and repurchased common stocks worth $110.4 million.
Amount spent on acquisitions, net of acquired cash, totaled $234.9 million. On May 2, 2022, IDEX completed the acquisition of KZValve.
Outlook
For third-quarter 2022, IDEX anticipates adjusted earnings of $1.98-$2.03 per share and 9-10% growth in organic sales from the respective year-ago period’s readings.
IEX predicts EPS of $1.80-$1.85 per share for third-quarter 2022.
For 2022, IDEX anticipates adjusted earnings of $7.88-$7.98 per share, higher than $7.50-$7.63 per share projected earlier. Full-year earnings are predicted to be $7.19-$7.29, higher than $6.87-$7.00 per share expected earlier.
Organic sales are predicted to grow approximately 10% for 2022.
Zacks Rank & Stocks to Consider
IEX currently carries a Zacks Rank #3 (Hold). Some better-ranked companies from the industrial products sector are discussed below:
Greif, Inc. (GEF - Free Report) presently sports a Zacks Rank #1 (Strong Buy). GEF delivered a trailing four-quarter earnings surprise of 22.9%, on average. You can see the complete list of today’s Zacks #1 Rank stocks.
GEF’s earnings estimates have increased 17.8% for fiscal 2022 (ending October 2022) in the past 60 days. Its shares have risen 16.7% in the past six months.
Titan International, Inc. presently flaunts a Zacks Rank of 1. Its earnings surprise in the last four quarters was 56.4%, on average.
In the past 60 days, TWI’s earnings estimates have increased 43.3% for 2022. The stock has surged 66.1% in the past six months.